Probiotics in Irritable Bowel Syndrome: An Immunomodulatory Strategy?

Journal of the American College of Nutrition

Volumn 26, Issue 6, 2007, Pages 684S-690S

  Quigley, Eamonn M M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

EVIDENCE BASED MEDICINE; HOSPITALIZATION; HUMAN; IMMUNOLOGY; INTESTINE MUCOSA; IRRITABLE COLON; MICROBIOLOGY; MUCOSAL IMMUNITY; PATHOLOGY; REVIEW; TREATMENT OUTCOME;

EVIDENCE-BASED MEDICINE; HUMANS; IMMUNITY, MUCOSAL; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; PROBIOTICS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 40749160476     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2007.10719648     Document Type: Article

References (100)

1. Hussein Z, Quigley EM: Complementary and alternative medicine in irritable bowel syndrome. Aliment Pharmacol Ther 23: 465-471, 2006.
2. Atkinson W, Sheldon TA, Shaath N, Whorwell PJ: Food elimination based on IgG antibodies in IBS: A randomised controlled trial. Gut 53: 1459-1464, 2004.
3. Zar S, Mincher L, Benson MJ, Kumar D: Food specific IgG4 antibodies guided exclusion diet improves symptoms and rectal compliance in IBS. Scand J Gastroenterol 40: 800-807, 2005.
4. Quigley EM: The use of probiotics in functional bowel disease. Gastroenterol Clin North Am 34: 533-545, 2005.
5. Schrezenmeir J, de Vrese M: Probiotics, prebiotics, and synbiotics-approaching a definition. Am J Clin Nutr 73(Suppl2): 361S-364S, 2001.
6. Gibson GR, Roberfroid MB: Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 125: 1401-1412, 1995.
7. Roberfroid MB: Prebiotics: preferential substrates for specific germs?. Am J Clin Nutr 73 (Suppl): 406S-409S, 2001.
8. Bouhnik Y, Flourie B, D'Agay-Abensour L, Pochart P, Gramet G, Durand M, Rambaud JC: Administration of transgalactooligosaccharides increases fecal bifidobacteria and modifies colonic fermentation metabolism in healthy humans. J Nutr 127: 444-448, 1997.
9. Duggan C, Gannon J, Walker WA: Protective nutrients and functional foods for the gastrointestinal tract. Am J Clin Nutr 75: 789-808, 2002.
10. Gnoth MJ, Kunz C, Kinne-Saffran E, Rudloff S: Human milk oligosaccharidases are minimally digested in vitro. J Nutr 130: 3014-3020, 2000.
11. Dai D, Walker WA: Prospective nutrients and bacterial colonization in the immature human gut. Adv Pediatr 46: 353-382, 1999.
12. McCarthy J, O'Mahony L, O'Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O'Sullivan GC, Kiely B, Collins JK, Shanahan F: Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 52: 975-980, 2003.
13. Madsen K, Cornish A, Soper P, McKaigney, C, Jijon H, Yachimel C, Doyle J, Jewell L, De Simone C: Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121: 580-591, 2001.
14. Hart AL, Lammers K, Brigidi P, Vitali B, Rizzello F, Gionchetti P, Campieri M, Kamm MA, Knight SC, Stagg AJ: Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 53: 1602-1609, 2004.
15. O'Mahony L, McCarthy J, Kelly P, Shanahan F, Quigley EM: Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128: 541-551, 2005.
16. O'Mahony L, O'Callaghan L, McCarthy J, Shilling D, Scully P, Sibartie S, Kavanagh E, Kirwan WO, Redmond RP, Collins JK, Shanahan F: Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans. Am J Physiol 290: G839-G845, 2006.
17. Jijon H, Backer J, Diaz H, Yeung H, Thiel D, McKagney C, De Simone C, Madsen K: DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 126: 1358-1373, 2004.
18. Drisko J, Bischoff B, Giles C, Adelson M, Rao RV, McCallum R: Evaluation of five probiotic products for label claims by DNA extraction and polymerase chain reaction analysis. Dig Dis Sci 50: 1113-1117, 2005.
19. Madden JA, Hunter JO: A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. Br J Nutr 88(Suppl 1): S67-S72, 2002.
20. Si JM, Yu YC, Fan YJ, Chen SJ.: Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 10: 1802-1805, 2004.
21. Malinen E, Rinttila T, Kajander K, Matto J, Kassinen A, Krobius L, Saarela M, Korpela R, Palva A: Analysis of the fecal microbiota of irritable bowel patients and healthy controls with realtime PCR. Am J Gastroenterol 100: 373-382, 2005.
22. Sun X, Cai G Wang WG: Observation on intestinal flora in patients of IBS after treatment of Chinese integrative medicine. Zhong Xi Yi Jie He Xue Bao 2: 340-342, 2004.
23. Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G: The fecal microbial population in the irritable bowel syndrome. Microbiologica 5: 185-194, 1982.
24. Bradley HK, Wyatt GM, Bayliss CE, Hunter JO: Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome. J Med Microbiol 23: 29-32, 1987.
25. King TS, Elia M, Hunter JO: Abnormal colonic fermentation in the irritable bowel syndrome. Lancet 352: 1187-1189, 1998.
26. Pimentel M, Chow EJ, Lin HC: Eradication of small bowel bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 95: 3503-3506, 2000.
27. Pimentel M, Chow E, Lin H: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 98: 412-419, 2003.
28. Pimentel M, Wallace D, Hallegua D, Chow E, Kong Y, Park S, Lin HC: A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Ann Rheum Dis 63: 450-452, 2004.
29. Pimentel M, Lin HC, Enayati P, van den Berg B, Lee HR, Chen JH, Park S, Kong Y, Conklin J: Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol 29: G1089-G1095, 2006.
30. Lin HC: Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 292: 852-858, 2004.
31. Pimentel M, Soffer EE, Chow EJ, Kong Y, Lin HC: Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test suggesting bacterial overgrowth. Dig Dis Sci 47: 2639-2642, 2002.
32. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I: A randomized double-blind placebo-controlled trial of rifaxamin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101: 326-333, 2006.
33. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y: The effect of a nonabsorbed antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 145: 557-563, 2006.
34. Quigley EM, Quera R: Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics and probiotics. Gastroenterology 130(2Suppl 1): S78-S90, 2006.
35. Jiang T, Savaiano DA: Modification of colonic fermentation by bifidobacteria and ph in vitro: impact on lactose metabolism, short-chain fatty acid, and lactate production. Dig Dis Sci 42: 2370-2377, 1997.
36. Johanson ML, Molin G, Ahrne S, Jeppsson B: Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 95: 1231-1238, 2000.
37. Kim HJ, Camilleri M, McKenzie S, Lempke MB, Burton DD: A randomized controlled trail of a probiotic, VSL#3 on gut transit and symptoms in diarrhoea-predominant IBS. Aliment Pharmacol Ther 17: 895-904, 2003.
38. Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G, Zinsmeister AR: A randomised controlled trial of probiotic combination VSL#3 and placebo in IBS with bloating: Neurogastroenterol Motil 17: 687-696, 2005.
39. Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R: A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 22: 387-394, 2005.
40. Niv E, Naftali T, Hallak R, Vaisman N: The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome-a double blind, placebo-controlled, randomized study. Clin Nutr 24: 925-931, 2005.
41. Tsuchiya J, Barreto R, Okura R, Kawakita S, Fesce E, Marotta F: Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 5: 169-174, 2004.
42. Sen S, Mulan MM, Parker TJ, Tarry SA, Hunter JO: Effect of Lactobacillus plantarum 299V on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 47: 2615-2620, 2002.
43. Bausserman M, Michail S: The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr 147: 197-201, 2005.
44. Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D: Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 152: 735-741, 2001.
45. Quigley EM: Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management. Chin J Dig Dis 8: 2-7, 2007.
46. Cotter PD, Hill C, Ross RP: Bacteriocins: developing innate immunity for food. Nat Rev Microbiol 3: 777-788, 2005.
47. Castigliuolo I, Riegler MF, Valenick L, La Mont JT, Pothoulakis C: Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 67: 302-307, 1999.
48. Spiller RC: Estimating the importance of infection in IBS. Am J Gastroenterol 98: 238-241, 2003.
49. Spiller RC: Postinfectious irritable bowel syndrome. Gastroenterology 124: 1662-1571, 2003.
50. Mearin F, Perez-Oliveras M, Perello A, Vinyet J, Ibanez A, Coderch J, Perona M: Dyspepsia and irritable bowel syndrome after a Salmonella outbreak: a one year follow-up cohort study. Gastroenterology 129: 98-104, 2005.
51. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF: Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev CD003048, 2004.
52. Gwee K-A, Leong Y-L, Graham C, McKendrick MW, Collins SM, Walters SJ, Underwood JE, Read NW: The role of psychological and biological factors in post-infective gut dysfunction. Gut 44: 400-406, 1999.
53. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 47: 804-811, 2000.
54. Dunlop SP, Jenkins D, Neal KR, Spiller RC: Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 125: 1651-1659, 2003.
55. Gwee KA, Collins SM, Read NW, Rajnakova A, Deng Y, Graham JC, McKendrick MW, Moochhala SM: Increased rectal mucosal expression of interleukin 1 beta in recently acquired post-infectious irritable bowel syndrome. Gut 52: 523-526, 2003.
56. Chadwick V, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I: Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 122: 1778-1783, 2002.
57. Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O'Mahony L, O'Mahony S, Shanahan F, Keeling PW: Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 130: 304-311, 2006.
58. Khalif IL, Quigley EM, Konovitch EA, Maximova ID: Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation. Dig Liver Dis 37: 838-849, 2005.
59. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, Akira S, Takeda K, Lee J, Takabayashi K, Raz E: Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126: 520-528, 2004.
60. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M: Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124: 1202-1209, 2003.
61. Mimuar T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA: Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53: 108-114, 2004.
62. Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV: Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 52: 91-93, 2003.
63. van der Veek PP, van der Berg M, de Kroon YE, Verspaget HW, Masclee AA: Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 100: 2510-2516, 2005.
64. Quigley EM: Disturbances of motility and visceral hypersensitivity in irritable bowel syndrome: biological markers or epiphenomenon. Gastroenterol Clin North Am. 34: 221-233, 2005.
65. Lawal A, Kern M, Sidhu H, Hofmann C, Shaker R: Novel evidence for hypersensitivity of visceral sensory neural circuitry in irritable bowel syndrome patients. Gastroenterology 130: 26-33, 2006.
66. Camilleri M: Testing the sensitivity hypothesis in practice: tools and methods, assumptions and pitfalls. Gut 51: i34-i40, 2002.
67. Bouin M, Plourde V, Boivin M, Riberdy M, Lupien F, Laganiere P, Verrier P, Poitras P: Rectal distension testing in patients with the irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 122: 1771-1777, 2002.
68. McKee DP, Quigley EMM: Intestinal motility in irritable bowel syndrome: Is IBS a motility disorder? Part 1: Definition of IBS and colonic motility. Dig Dis Sci 38: 1761-1772, 1993.
69. McKee DP, Quigley EMM: Intestinal motility in irritable bowel syndrome: Is IBS a motility disorder? Part 2: Motility of the small bowel, esophagus, stomach and gall bladder. Dig Dis Sci 38: 1763-1782, 1993.
70. Quigley EMM: Disturbances in small bowel motility. Bailliere's Best Pract Res Clin Gastroenterol 13: 385-395, 1999.
71. Collins SM: A case for an immunological basis for irritable bowel syndrome. Gastroenterology 122: 2078-2080, 2002.
72. Mayer EA, Collins SM: Evolving pathophysiological models of functional gastrointestinal disorders. Gastroenterology 122: 2032-2048, 2002.
73. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R: Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126: 693-702, 2004.
74. Verdu EF, Bercik P, Bergonzelli GE, Huang XX, Blenerhasset P, Rochat F, Fiaux M, Mansourian R, Corthesy-Theulaz I, Collins SM: Lactobacillus paracasei normalizes muscle hypercontractiltiy in a murine model of postinfective gut dysfunction. Gastroenterology 127: 826-837, 2004.
75. Verdu EF, Bercik P, Verma-Gandhu M, Huang X-X, Blenerhasset P, Jackson W, Mao Y, Wang L, Rochat F, Collins SM: Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 55: 182-190, 2006.
76. Ait-Belgnaoui A, Han W, Lamine F, Eutamene H, Fioramonti J, Bueno L, Theodorou V: Lactobacillus farciminis treatment suppresses stress-induced visceral hypersensitivity: a possible action through interaction with epithelial cells cytoskeleton contraction. Gut 55: 1090-1094, 2006.
77. Kamiya T, Wang L, Forsythe P, Goettsche G, Mao Y, Wang Y, Tougas G, Bienenstock J: Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut 55: 191-196, 2006.
78. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L Dubuquoy C, Merour E, Geboes K, Chamaillard M, Ouwehand A, Leyer G, Carcano D, Colombel JF, Ardid D, Desreumaux P: Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 13: 35-37, 2007.
79. Resta-Lenert S, Barrett KE: Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 52: 988-997, 2003.
80. Zareie M, Johnson-Henry KC, Jury J, Yang PC, Ngan BY, McKay DM, Soderholm JD, Perdue MH, Sherman PM: Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut 55: 1553-1560, 2006.
81. Hobday D, Thompson DG: Role of functional brain imaging in gastroenterology in health and disease. Digest Liver Dis 32: 101-103, 2000.
82. Aziz Q, Thompson DG: Clinical relevance of the gut brain axis. Gastroenterology 114: 559-578, 1997.
83. Mertz H, Morgan V, Tanner G, Pickens D, Price R, Shyr Y, Kessler R: Regional cerebral activation in irritable bowel syndrome with painful and nonpainful stimuli. Gastroenterology 118: 842-848, 2000.
84. Patacchioli FR, Angelucci L, Delleba G, Monnazzi P, Leci O: Actual stress, psychopathology and salivary cortisol levels in the irritable bowel syndrome (IBS). J Endocrinol Invest 24: 173-177, 2001.
85. Ellenbruch S, Orr WC: Diarrhea-and constipation-predominant IBS patients differ in postprandial autonomic and cortisol responses. Am J Gastroenterol 96: 460-466, 2001.
86. Beishuizen A, Thijs LG: Endotoxin and the hypothalamicpituitary-adrenal (HPA) axis. J Endotoxin Res 9: 3-24, 2003.
87. O'Brien SM, Scully P, Scott LV, Dinan TG: Cytokine profiles in bipolar affective disorders: focus on acutely ill patients. Affect Disord 90: 263-267, 2006.
88. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, Desimone C, Song XY, Diehl AM: Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37: 343-350.
89. Sheil B, McCarthy J, O'Mahony L, Bennett MW, Ryan P, Fitzgibbon JJ, Kiely B, Collins JK, Shanahan F: Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut 53: 694-700, 2004.
90. Whitehead WE, Palsson O, Jones KR: Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 122: 1140-1156, 2002.
91. Niedzielin K, Kordecki H, Birkenfeld B: A controlled, doubleblind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 13: 1143-1147, 2001.
92. Halpern GM, Prindiville T, Blankenburg M, Hsia T, Gershwin ME: Treatment of irritable bowel syndrome with lacteol fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol 91: 1579-1585, 1996.
93. O'Sullivan MA, O'Morain CA: Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebocontrolled crossover study. Dig Liver Dis 32: 302-304, 2000.
94. Nobaek S, Johanson ML, Molin G, Ahrne S, Jeppsson B: Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 95: 1231-1238, 2000.
95. Hamilton-Miller JMT: Probiotics in the Management of Irritable Bowel Syndrome: A Review of Clinical Trials. Microb Ecol Health Dis 13: 212-216, 2001.
96. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EMM: Efficacy of an encapsulated probiotic Bifidobacterium Infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol, in press, 2006.
97. Evans BW, Clark WK, Moore DJ, Whorwell PJ: Tegaserod for the treatment of irritable bowel syndrome. The Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD003960. DOI: 10.1002/14651858.CD003960.pub2.
98. Cremonini F, Delgado-Aros S, Camilleri M: Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 15: 79-86, 2003.
99. Fanigliulo L, Comparato G, Aragona G, Cavallaro L, Iori V, Maino M, Cavestro GM, Soliani P, Sianesi M, Franze A, Di Mario F: Role of gut microflora and probiotic effects in the irritable bowel syndrome. Acta Biomed. 77: 85-89, 2006.
100. Drisko J, Bischoff B, Hall M, McCallum R.: Treating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics. J Am Coll Nutr. 25: 514-522, 2006.